50 research outputs found

    NESSiE: The Experimental Sterile Neutrino Search in Short-Base-Line at CERN

    Full text link
    Several different experimental results are indicating the existence of anomalies in the neutrino sector. Models beyond the standard model have been developed to explain these results and involve one or more additional neutrinos that do not weakly interact. A new experimental program is therefore needed to study this potential new physics with a possibly new Short-Base-Line neutrino beam at CERN. CERN is actually promoting the start up of a New Neutrino Facility in the North Area site, which may host two complementary detectors, one based on LAr technology and one corresponding to a muon spectrometer. The system is doubled in two different sites. With regards to the latter option, NESSiE, Neutrino Experiment with Spectrometers in Europe, had been proposed for the search of sterile neutrinos studying Charged Current (CC) muon neutrino and antineutrino ineractions. The detectors consists of two magnetic spectrometers to be located in two sites:"Near" and "Far" from the proton target of the CERN-SPS beam. Each spectrometer will be complemented by an ICARUS-like LAr target in order to allow also Neutral Current (NC) and electron neutrino CC interactions reconstruction.Comment: Prensented at the Lake Louise Winter 2013 Conference, Banff, Alberta, Canada, 17-23 February 201

    DsTau: Study of tau neutrino production with 400 GeV protons from the CERN-SPS

    Full text link
    In the DsTau experiment at the CERN SPS, an independent and direct way to measure tau neutrino production following high energy proton interactions was proposed. As the main source of tau neutrinos is a decay of Ds mesons, produced in proton-nucleus interactions, the project aims at measuring a differential cross section of this reaction. The experimental method is based on a use of high resolution emulsion detectors for effective registration of events with short lived particle decays. Here we present the motivation of the study, details of the experimental technique, and the first results of the analysis of the data collected during test runs, which prove feasibility of the full scale study of the process in future

    First Direct Observation of Collider Neutrinos with FASER at the LHC

    Get PDF
    We report the first direct observation of neutrino interactions at a particle collider experiment. Neutrino candidate events are identified in a 13.6 TeV center-of-mass energy pppp collision data set of 35.4 fb1{}^{-1} using the active electronic components of the FASER detector at the Large Hadron Collider. The candidates are required to have a track propagating through the entire length of the FASER detector and be consistent with a muon neutrino charged-current interaction. We infer 15313+12153^{+12}_{-13} neutrino interactions with a significance of 16 standard deviations above the background-only hypothesis. These events are consistent with the characteristics expected from neutrino interactions in terms of secondary particle production and spatial distribution, and they imply the observation of both neutrinos and anti-neutrinos with an incident neutrino energy of significantly above 200 GeV.Comment: Submitted to PRL on March 24 202

    First neutrino interaction candidates at the LHC

    Get PDF
    FASERν\nu at the CERN Large Hadron Collider (LHC) is designed to directly detect collider neutrinos for the first time and study their cross sections at TeV energies, where no such measurements currently exist. In 2018, a pilot detector employing emulsion films was installed in the far-forward region of ATLAS, 480 m from the interaction point, and collected 12.2 fb1^{-1} of proton-proton collision data at a center-of-mass energy of 13 TeV. We describe the analysis of this pilot run data and the observation of the first neutrino interaction candidates at the LHC. This milestone paves the way for high-energy neutrino measurements at current and future colliders.Comment: Auxiliary materials are available at https://faser.web.cern.ch/fasernu-first-neutrino-interaction-candidate

    The FASER Detector

    Get PDF
    FASER, the ForwArd Search ExpeRiment, is an experiment dedicated to searching for light, extremely weakly-interacting particles at CERN's Large Hadron Collider (LHC). Such particles may be produced in the very forward direction of the LHC's high-energy collisions and then decay to visible particles inside the FASER detector, which is placed 480 m downstream of the ATLAS interaction point, aligned with the beam collisions axis. FASER also includes a sub-detector, FASERν\nu, designed to detect neutrinos produced in the LHC collisions and to study their properties. In this paper, each component of the FASER detector is described in detail, as well as the installation of the experiment system and its commissioning using cosmic-rays collected in September 2021 and during the LHC pilot beam test carried out in October 2021. FASER will start taking LHC collision data in 2022, and will run throughout LHC Run 3

    Research and Development for Near Detector Systems Towards Long Term Evolution of Ultra-precise Long-baseline Neutrino Experiments

    Get PDF
    With the discovery of non-zero value of θ13\theta_{13} mixing angle, the next generation of long-baseline neutrino (LBN) experiments offers the possibility of obtaining statistically significant samples of muon and electron neutrinos and anti-neutrinos with large oscillation effects. In this document we intend to highlight the importance of Near Detector facilities in LBN experiments to both constrain the systematic uncertainties affecting oscillation analyses but also to perform, thanks to their close location, measurements of broad benefit for LBN physics goals. A strong European contribution to these efforts is possible

    Febrile neutropenia due to H1N1 infection: Rare entity

    No full text
    Background: Febrile neutropenia is one of the most feared complications in actively treated patients in oncology clinics. The impact of H1N1 infection on the management of the febrile neutropenia in endemic areas, especially if the patient is presented with pulmonary symptoms, is not clear. Case report: A Forty seven year old male patient diagnosed with mantle cell lymphoma, admitted to our center with neutropenic fever 8 days after chemotherapy. The patient revealed classical symptoms of influenza like headache and myalgia and also had rhonchus and cough supporting lower respiratory tract infection. He was finally diagnosed as influenza A (H1N1) infection. Conclusion: Influenza infection is an important etiological agent in immunocompromised hosts, namely neutropenic patients, which cause significant morbidity and mortality. Viral etiology and antiviral treatment should also be considered in suspected patients especially during epidemics and pandemics

    Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment?

    Get PDF
    Background: Standard treatment of colorectal cancer includes both cytostatic chemotherapy and targeted therapies. Bevacizumab, targeting the VEGF receptor, is one of the primary targeted therapies that achieve better response rate and survival rate as compared to combination chemotherapy. To the best of our knowledge, there is no established single marker that can be used as a predictive marker in bevacizumab therapy. Material/Methods: We enrolled 24 patients with the diagnosis of metastatic colorectal cancer in our study. During the study, 2 blood samples were drawn from patients before the first cycle and after the sixth cycle of bevacizumab therapy. Serum levels of VEGF, ANG II, and NO were recorded. Results: While the change across VEGF levels was found to be a statistically significant decreasing trend (p=0.009), this decrease was not found to be correlated with treatment response and hypertension development. Additionally, no statistically significant difference was found in terms of NO and ANG II levels. Conclusions: This study showed a significant decrease in serum VEGF, but failed to show a significant change in NO and ANG II levels during bevacizumab treatment. Although no significant correlation was found between the presence of hypertension and markers, most patients (83%) had an increase in their blood pressure. Our results suggest that dynamic monitoring of NO and ANG II, along with VEGF, may not be useful as predictive markers for bevacizumab treatment in colorectal cancer